

# Cornelia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7370962/publications.pdf>

Version: 2024-02-01

38  
papers

3,802  
citations

236925

25  
h-index

330143

37  
g-index

38  
all docs

38  
docs citations

38  
times ranked

4867  
citing authors

#	ARTICLE	IF	CITATIONS
1	TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. <i>Nature Medicine</i> , 2021, 27, 419-425.	30.7	156
2	Current status of therapeutic HPV vaccines. <i>Gynecologic Oncology</i> , 2020, 156, 503-510.	1.4	29
3	A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3). <i>Gynecologic Oncology</i> , 2020, 157, 188-194.	1.4	34
4	Towards identifying new therapeutic targets in cancers attributable to HPV. <i>Gynecologic Oncology</i> , 2018, 149, 225-226.	1.4	0
5	Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 276-294.	7.0	32
6	A primary role for human central memory cells in tissue immunosurveillance. <i>Blood Advances</i> , 2018, 2, 292-298.	5.2	27
7	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. <i>JCI Insight</i> , 2018, 3, .	5.0	110
8	Defining the genetic susceptibility to cervical neoplasiaâ€”A genome-wide association study. <i>PLoS Genetics</i> , 2017, 13, e1006866.	3.5	105
9	Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16025.	4.4	30
10	A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3). <i>Gynecologic Oncology</i> , 2016, 140, 245-252.	1.4	90
11	Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cellâ€”Mediated Tumor Control in the Genital Tract. <i>Clinical Cancer Research</i> , 2016, 22, 657-669.	7.0	71
12	Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2015, 386, 2078-2088.	13.7	529
13	Intramuscular Therapeutic Vaccination Targeting HPV16 Induces T Cell Responses That Localize in Mucosal Lesions. <i>Science Translational Medicine</i> , 2014, 6, 221ra13.	12.4	178
14	HPV Infectionâ€”Associated Cancers: Next-Generation Technology for Diagnosis and Treatment. <i>Cancer Immunology Research</i> , 2014, 2, 937-942.	3.4	9
15	Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNÎ³. <i>Clinical Cancer Research</i> , 2014, 20, 5456-5467.	7.0	49
16	Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. <i>Gynecologic Oncology</i> , 2013, 128, 155-159.	1.4	82
17	Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3786-3791.	1.6	317
18	New technologies for cervical cancer screening. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 233-242.	2.8	25

#	ARTICLE	IF	CITATIONS
19	Karyometry in atypical endometrial hyperplasia: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 125, 129-135.	1.4	5
20	Disparities in Human Papillomavirus Vaccine Completion Among Vaccine Initiators. <i>Obstetrics and Gynecology</i> , 2011, 118, 14-20.	2.4	56
21	Impact of payer status on treatment of cervical cancer at a tertiary referral center. <i>Gynecologic Oncology</i> , 2011, 122, 324-327.	1.4	7
22	Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 799-803.	4.2	40
23	Human Papillomavirus 16-Associated Cervical Intraepithelial Neoplasia in Humans Excludes CD8 T Cells from Dysplastic Epithelium. <i>Journal of Immunology</i> , 2010, 185, 7107-7114.	0.8	109
24	A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3. <i>Clinical Cancer Research</i> , 2009, 15, 361-367.	7.0	186
25	Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity. <i>Journal of Immunology</i> , 2009, 183, 7161-7168.	0.8	170
26	Development of therapeutic HPV vaccines. <i>Lancet Oncology</i> , The, 2009, 10, 975-980.	10.7	88
27	Human Papillomavirus Vaccination Should Be Offered to Young Males: Counterpoint. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 809-809.	2.5	4
28	Human papillomavirus screening and vaccines for cancer prevention: what is on the horizon?. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 295-303.	0.2	1
29	Gene Expression Analysis of Preinvasive and Invasive Cervical Squamous Cell Carcinomas Identifies <i>HOXC10</i> as a Key Mediator of Invasion. <i>Cancer Research</i> , 2007, 67, 10163-10172.	0.9	205
30	Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia. <i>Cancer</i> , 2006, 106, 812-819.	4.1	525
31	Active and Passive Cigarette Smoking and the Risk of Cervical Neoplasia. <i>Obstetrics and Gynecology</i> , 2005, 105, 174-181.	2.4	82
32	Prospects for therapeutic HPV vaccines. <i>Gynecologic Oncology</i> , 2005, 99, S249-S250.	1.4	1
33	Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA Phenotype. <i>Clinical Cancer Research</i> , 2005, 11, 4717-4723.	7.0	205
34	Effectiveness of Screening for Cervical Cancer in an Inpatient Hospital Setting. <i>Obstetrics and Gynecology</i> , 2004, 103, 310-316.	2.4	12
35	Heterogeneous Etiology of Squamous Carcinoma of the Vulva. <i>Obstetrics and Gynecology</i> , 1996, 87, 59-64.	2.4	157
36	Human Papillomavirus-Specific Serologic Response in Vulvar Neoplasia. <i>Gynecologic Oncology</i> , 1996, 63, 200-203.	1.4	27

#	ARTICLE	IF	CITATIONS
37	Human papillomavirus and the pathogenesis of vulvar carcinoma. <i>Current Opinion in Obstetrics and Gynecology</i> , 1992, 4, 582-585.	2.0	23
38	The distribution of factor XIIIa-positive cells in the human fetus and placenta. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1992, 420, 513-518.	1.4	26